MedTrace Logo

A Study of a Candidate COVID-19 Vaccine (COV003)

NCT04536051 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 10300

Last updated 2020-11-27

No results posted yet for this study

Summary

A Randomized, Controlled, Phase III Study to Determine the Safety, Efficacy, and Immunogenicity of the Non-Replicating ChAdOx1 nCoV-19 Vaccine.

Conditions

  • Coronavirus

Interventions

BIOLOGICAL

ChAdOx1 nCoV-19 single dose + paracetamol

Single dose of ChAdOx1nCOV19 vaccine, 5x10\^10 vp + paracetamol

BIOLOGICAL

MenACWY single dose + paracetamol

Single dose of MenACWY + paracetamol

BIOLOGICAL

ChAdOx1 nCoV-19 two dose + paracetamol

Two dose of ChAdOx1 nCoV-19 vaccine, 5x10\^10vp (prime) and 0.5mL boost (3.5 - 6.5 × 10\^10 vp), 4-12 weeks apart + paracetamol

BIOLOGICAL

MenACWY prime & saline placebo boost + paracetamol

MenACWY prime, and Saline Placebo boost (0.5mL) + paracetamol

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Andrew Pollard, Prof · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-02
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04536051 on ClinicalTrials.gov